Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2001-3-22
pubmed:abstractText
The effect of glucagon and its second messenger cAMP on cytochrome P450 2C11 (CYP2C11) expression was investigated in primary hepatocytes cultured on Matrigel. Glucagon, epinephrine, forskolin, and the cAMP derivatives dibutyryl cAMP, (S(p))-adenosine 3',5' cyclic monophosphothioate (S(p)-cAMPS), and 8-(4-chlorophenylthio)-cAMP, but not dideoxyforskolin, all down-regulated CYP2C11 mRNA expression to approximately 20% of control levels in a concentration-dependent manner. Using the transcriptional inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, CYP2C11 mRNA was found to have a half-life of 9.8 h. The kinetics of suppression of CYP2C11 mRNA by glucagon and forskolin was similar to that obtained with the transcriptional inhibitor, suggesting that glucagon and forskolin act at the transcriptional level. CYP2C11 expression was more sensitive to suppression by glucagon at low insulin concentrations than at higher concentrations. (R(p))-Adenosine 3',5' cyclic monophosphothioate inhibited the down-regulation of CYP2C11 by S(p)-cAMPS, consistent with a competitive blockade of protein kinase A activation. These results suggest a role for glucagon in the down-regulation of CYP2C11 in diabetic rats, and provide a possible explanation for the known sensitivity of this cytochrome P450 to suppression in various stress and disease models.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-3565
pubmed:author
pubmed:issnType
Print
pubmed:volume
297
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
174-80
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:11259542-Animals, pubmed-meshheading:11259542-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:11259542-Cells, Cultured, pubmed-meshheading:11259542-Cyclic AMP, pubmed-meshheading:11259542-Cytochrome P-450 Enzyme System, pubmed-meshheading:11259542-Diabetes Mellitus, pubmed-meshheading:11259542-Down-Regulation, pubmed-meshheading:11259542-Epinephrine, pubmed-meshheading:11259542-Fasting, pubmed-meshheading:11259542-Forskolin, pubmed-meshheading:11259542-Gene Expression Regulation, Enzymologic, pubmed-meshheading:11259542-Glucagon, pubmed-meshheading:11259542-Inflammation, pubmed-meshheading:11259542-Insulin, pubmed-meshheading:11259542-Liver, pubmed-meshheading:11259542-Male, pubmed-meshheading:11259542-Rats, pubmed-meshheading:11259542-Rats, Sprague-Dawley, pubmed-meshheading:11259542-Steroid 16-alpha-Hydroxylase, pubmed-meshheading:11259542-Steroid Hydroxylases
pubmed:year
2001
pubmed:articleTitle
Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation in diabetes, fasting, and inflammation.
pubmed:affiliation
Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.